Forecast
The analysts' average price target is €64.99 (+48.11%). The median is €64.72 (+47.49%).
| Buy |
13 |
| Hold |
2 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Scholar Rock clarifies FDA requirements for ISEMBYLD, shares fall sharply
Scholar Rock confirmed that the FDA requires post‑marketing conditions for ISEMBYLD, including a study on safety in pregnancy and 15‑day adverse‑event reporting for bone fractures. Management had previously (and incorrectly) stated that no such conditions existed. The stock then fell 6.4% to $51.85 and declined 9.7% on the week. Scholar Rock said it will carry out the requested studies and reporting in line with FDA requirements; analysts subsequently adjusted ratings and price targets. » More on de.investing.com
FDA grants approval for ISEMBYLD; Scholar Rock stock rises
The FDA approved ISEMBYLD (apitegromab-mstn) as the first muscle-specific treatment for spinal muscular atrophy in adults and children aged two and older who are already receiving an SMN2-directed therapy. The news pushed Scholar Rock’s stock up about 9% pre-market to $60.45 and converts the company into a commercial biopharma company. Several analysts sharply raised price targets and reiterated buy ratings; apitegromab is projected to generate billions in sales by 2035. Scholar Rock reports roughly $492 million in cash and has independent fill-and-finish and manufacturing capabilities for the product launch. » More on de.investing.com
Scholar Rock receives FDA approval for Isembyld to treat SMA
The FDA has approved Isembyld (Apitegromab‑mstn) for the treatment of spinal muscular atrophy in patients aged two and older. The approval is based on the phase‑3 SAPPHIRE study, in which patients receiving Isembyld in addition to standard therapy showed a significant improvement on the Hammersmith scale after one year; 34.2% achieved an increase of at least three points versus 13.5% with placebo. The US commercial launch has begun, the stock climbed more than 14% to an all‑time high, and Scholar Rock is shifting from a clinical biotech company to a commercial drugmaker. » More on deraktionaer.de
Scholar Rock prepares for FDA decision on apitegromab
Weeks before the PDUFA date on September 30, 2026, Scholar Rock highlights late Phase III data on apitegromab as well as secured commercial production and go‑to‑market infrastructure. After an earlier Complete Response Letter over manufacturing issues, the company moved commercial fill‑finish production to an alternative site and says it has already produced commercial vials there. Management emphasizes statistically significant Phase III results, high treatment adherence, and prepared sales, nursing and patient‑support structures for the US, with plans for Europe and Japan. » More on de.investing.com
Scholar Rock nears approval for apitegromab
At the Cantor Fitzgerald Global Healthcare Conference, Scholar Rock said the FDA has identified compliance with manufacturing requirements as the only remaining approval hurdle and that the company has since established a contractually committed alternative fill-and-finish facility. The crucial PDUFA date is September 30, 2026; management is holding intensive talks with the FDA about labeling and safety data. Scholar Rock has roughly $500 million in cash, sees worldwide market potential in the billions, and expects initial but manageable reimbursement and market-access hurdles during the first three to five quarters after launch. » More on de.investing.com
Financials
In the last quarter, SCHOLAR ROCK HLDG DL-,001 had revenue of €503.22k and net profit of -€94.68m
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 503.22k | - |
| Gross profit | 496.16k | 101.15% |
| Net profit | -94.68m | 8.69% |
| EBITDA | -90.36m | 5.55% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €5.35bn |
Number of shares | 122m |
52-week high/low | €56.30 - €35.27 |
| Dividends | No |
Beta | 0.62 |
P/E ratio | -14.95 |
PEG ratio | 28.66 |
P/B ratio | 37.77 |
P/S ratio | 10,301.85 |
Company profile
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
| Name | SCHOLAR ROCK HLDG DL-,001 |
| CEO | David L. Hallal |
| Headquarters | Cambridge,
ma USA |
| Website | |
| Sector | Consumer Staples |
| Industry | Food Products |
| IPO | 25/05/2018 |
| Employees | 289 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | SRRK |
Frankfurt | 2QK.F |
Düsseldorf | 2QK.DU |
München | 2QK.MU |